Late effects among long-term survivors of childhood acute leukemia in The Netherlands: a Dutch Childhood Leukemia Study Group Report. 1995

A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
Dutch Childhood Leukemia Study Group, Hague, The Netherlands.

Late events and side effects are reported in 392 children cured of leukemia. They originated from 1193 consecutively newly diagnosed children between 1972 and 1982, in first continuous complete remission for at least 6 y after diagnosis, and were treated according to Dutch Childhood Leukemia Study Group protocols (70%) or institutional protocols (30%), all including cranial irradiation for CNS prophylaxis. Data on late events (relapses, death in complete remission, and second malignancies) were collected prospectively after treatment; late side effects were retrospectively collected by a questionnaire, completed by the responsible pediatrician. The event-free survival of the 6-y survivors at 15 y after diagnosis was 92% (+/- 2%). Eight late relapses and nine second malignancies were diagnosed, two children died in first complete remission of late toxicity of treatment, and one child died in a car accident. The most important long-term side effects reported were learning disabilities (50%), short stature, obesity, and delayed pubertal development. No increase in the incidence of cardiovascular, pulmonary, urogenital, or gastrointestinal tract diseases or an increased vulnerability of the musculoskeletal system was found. However, prolonged follow-up is necessary to study the full-scale late effects of cytostatic treatment and radiotherapy administered during childhood.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D012042 Registries The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers. Parish Registers,Population Register,Parish Register,Population Registers,Register, Parish,Register, Population,Registers, Parish,Registers, Population,Registry
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
January 1988, Pediatrics,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
July 2009, Clinical pediatrics,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
August 2011, Pediatric hematology and oncology,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
August 1996, Neuropediatrics,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
November 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
December 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
November 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
June 2010, International journal of hematology,
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
April 1999, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
A van der Does-van den Berg, and G A de Vaan, and J F van Weerden, and K Hählen, and M van Weel-Sipman, and A J Veerman
October 1988, Anales espanoles de pediatria,
Copied contents to your clipboard!